newsfilter
← Latest News
GlobeNewswire·

RVL Pharmaceuticals plc Announces Preliminary First Quarter 2022 UPNEEQ® Net Product Sales Results

-- Expects first quarter 2022 preliminary UPNEEQ net product sales of approximately $5.9 million, representing an increase of 90% from the fourth quarter 2021 -- -- Reaffirms fourth quarter 2022 guidance of $20 to 25 million in UPNEEQ net product sale